Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.
Ungvari
Zoltan I
ZI
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism* / Q000517:prevention & control; D055415:Bone Morphogenetic Protein 4; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004727:Endothelium / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D014652:Vascular Diseases / Q000378:metabolism / Q000517:prevention & control
C525809:BMP4 protein, human; D055415:Bone Morphogenetic Protein 4; D019485:Bone Morphogenetic Proteins; D000109:Acetylcholine